Neurotech International (ASX:NTI) - 주가, 뉴스 및 분석

NTI 주식 개요

임상 단계의 바이오 의약품 개발 회사인 Neurotech International Limited는 호주에서 의료 기기 및 솔루션의 연구, 설계, 개발, 제조에 종사하고 있습니다. 자세한 내용

NTI 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	2/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

수익은 연간 44.67% 증가할 것으로 예상됩니다.

위험 분석

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

의미 있는 수익이 없습니다. ( A$3M )

의미 있는 시가총액이 없습니다. ( A$63M )

Neurotech International Limited 경쟁사

CurveBeam AI

ASX:CVB

AU$41.4m

Micro-X

ASX:MX1

AU$39.0m

CardieX

ASX:CDX

AU$35.3m

SomnoMed

ASX:SOM

AU$60.5m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Neurotech International
과거 주가
현재 주가	AU$0.066
52주 최고치	AU$0.13
52주 최저치	AU$0.048
베타	1.48
11개월 변경	29.41%
3개월 변경 사항	-8.33%
1년 변경 사항	15.79%
33년 변화	3.13%
5년 변화	266.67%
IPO 이후 변화	-76.84%

최근 뉴스 및 업데이트

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Nov 19

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 19

Recent updates

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Nov 19

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 19

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Jan 28

We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully

Oct 14

Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

Jul 01

Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?

Jan 21

Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?

Oct 06

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

May 18

We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate

Dec 21

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 04

Need To Know: Neurotech International Limited (ASX:NTI) Insiders Have Been Selling Shares

Dec 08

주주 수익률

	NTI	AU Medical Equipment	AU 마켓
7D	22.2%	0.6%	1.4%
1Y	15.8%	15.3%	17.7%

수익률 대 산업: NTI 지난 1년 동안 15.3 %를 반환한 Australian Medical Equipment 산업과 일치했습니다.

수익률 대 시장: NTI 지난 1년 동안 17.7 %를 반환한 Australian 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is NTI's price volatile compared to industry and market?
NTI volatility
NTI Average Weekly Movement	8.7%
Medical Equipment Industry Average Movement	9.0%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

안정적인 주가: NTI 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: NTI 의 주간 변동성( 9% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2016	n/a	Peter James Griffiths	www.neurotechinternational.com

임상 단계의 바이오 의약품 개발 회사인 Neurotech International Limited는 호주에서 의료 기기 및 솔루션의 연구, 설계, 개발, 제조에 종사하고 있습니다. 이 회사는 여러 소아 신경 장애를 위한 NTI164와 델타 밴드 뇌 활동이 높은 자폐 아동의 참여와 이완을 향상시키기 위한 임상적으로 입증된 가정 요법인 Mente의 개발 및 상용화에 주력하고 있습니다. 또한 의료 연구 프로젝트 수행과 기술 기기 개발에도 참여하고 있습니다.

Neurotech International Limited 기본 사항 요약

Neurotech International 의 수익과 매출은 시가총액과 어떻게 비교하나요?
NTI 기본 통계
시가총액	AU$63.11m
수익(TTM)	-AU$5.07m
수익(TTM)	AU$3.18m

21.5x

P/S 비율

-13.5x

P/E 비율

NTI 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
NTI 손익 계산서(TTM)
수익	AU$3.18m
수익 비용	AU$7.83k
총 이익	AU$3.17m
기타 비용	AU$8.24m
수익	-AU$5.07m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.0049
총 마진	99.75%
순이익 마진	-159.54%
부채/자본 비율	0%

NTI 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

NTI 주식 개요

보상

위험 분석

Neurotech International Limited 경쟁사

ASX:CVB

AU$41.4m

ASX:MX1

AU$39.0m

ASX:CDX

AU$35.3m

ASX:SOM

AU$60.5m

가격 내역 및 성능

최근 뉴스 및 업데이트

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Now 21% overvalued

Now 20% overvalued

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Now 21% overvalued

Now 20% overvalued

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Independent Non-Executive Director exercised options to buy AU$114k worth of stock.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Neurotech International Limited to Report Q4, 2023 Results on Jul 26, 2023

New minor risk - Share price stability

Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

First half 2023 earnings released: AU$0.48 loss per share (vs AU$0.003 loss in 1H 2022)

Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial

Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension

Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

Neurotech International Limited to Report Q3, 2023 Results on Jan 30, 2023

Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?

Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Neurotech International Limited, Annual General Meeting, Nov 23, 2022

Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164

Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS

Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?

Neurotech International Limited Provides Autism Spectrum Disorder Phase I/II Clinical Trial Update

Less than half of directors are independent

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.015 loss in FY 2021)

Neurotech International Limited Announces Currently Finalising a Pivotal Phase II/III Clinical Trial Design to be Conducted in Australia

Neurotech International ORDINARY FULLY PAID to Be Deleted from OTC Equity

Neurotech International Limited Announces Executive Changes

Neurotech International Limited Announces Results with NTI164 in Paediatric ASD

High number of new directors

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Neurotech International Limited Announces Important Developments Relating to the Study Protocol Assessing NTI164 in Children with Autism Spectrum Disorder

High number of new directors

Neurotech International Limited Announces Successful Developments Relating to Safety and Tolerability of NTI164 and Key Behavioural Parameters That Impact Autism Spectrum Disorder Patients

Neurotech International Limited Appoints Alexandra Andrews as Chief Executive Officer, Effective 8 March 2022

We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate

Neurotech International Limited Announces Nti164 Clinical Program Update

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2020)

Neurotech International Limited Announces the Continuation of Its Pre-Clinical Program in Neuro-Inflammatory Disease Models In-Line with Research and Development Pathway

Neurotech International Limited Initiates Phase I/II Open Label Study into Autism

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.

Neurotech International Limited Announces Strategic Cultivation Partnership with CannaPacific Limited

Neurotech International Limited Announces the Expansion of Its Exclusive License with Dolce Cann Global Pty Ltd

Neurotech International Limited Provides an Update on Clinical Study Program

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.